TrialLung cancer (Amsterdam, Netherlands)2011

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.

Paul K Paik et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.